Click here to find out if $ACT is a buy hold or sell.
Watching these stocks. $POT $HAR $XLY $GS
http://www.barchart.com/opinions/stocks/ACT
Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...
Continue Reading
Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...
Continue Reading
Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....
Continue Reading
A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...
Continue Reading
Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...
Continue Reading
Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...
Continue Reading
Massive Growth and Strategic Investment in DigitalXForce Now here’s a company that’s shaking things up—DigitalXForce. Right on the back of a staggering 514% growth, they’ve corralled a strategic investment from Arsenal Growth Equity. If you blink, you might miss just how fast they’re sprinting through the tech landscape. Institutional Support Backing the...
Continue Reading
Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...
Continue Reading
Itafos Strengthens Financial Position with Credit Facility Amendments Itafos Inc. (TSX-V: IFOS) has recently taken a significant step to enhance its financial flexibility and liquidity by amending its credit facilities. This development is vital for the company's ongoing projects, particularly the H1/NDR initiative, which aims to extend the operational life of the Conda...
Continue Reading
Understanding Renault S.A.’s Voting Rights and Share Capital Renault S.A., a notable player in the automotive industry, recently made significant disclosures regarding its voting rights and share capital. These updates are essential for shareholders, investors, and market analysts as they navigate financial decisions surrounding the company. Key Details Disclosed by...
Continue Reading
Embracing Innovation in Sports Betting In the rapidly changing world of sports betting, innovation is key. RealBookies.com has emerged as a trailblazer, offering cutting-edge sportsbook software solutions designed to cater to both aspiring entrepreneurs and seasoned operators. By leveraging advanced technology, they empower users to thrive in the global sports wagering...
Continue Reading
Immunovia AB (publ) saw a hefty spike in its registered shares recently, totaling 169,711,476 as of September 2024. This surge came on the heels of a rights issue resolved by the board—essentially a cash grab to shore up their footing in the cutthroat healthcare sector. Traders caught wind of these moves, but let's break down what's really brewing under the surface....
Continue Reading
Bloomberg Law Recognizes Innovative Law School Programs Bloomberg Law has recently unveiled the ten finalists for its esteemed Law School Innovation Program. This initiative, now running into its third year, is dedicated to identifying and honoring law schools that are at the forefront of educational innovation. The focus of this year's program is to enhance career...
Continue Reading